Drugmaker AbbVie Trims Profit Forecasts On IPR&D Expenses

Drugmaker AbbVie Trims Profit Forecasts On IPR&D Expenses

(Reuters) -AbbVie Inc on Wednesday lowered its full-year and first-quarter profit expectations, citing a $150 million hit from acquired in-process research and development (IPR&D) and milestone expenses. The drugmaker’s shares were down nearly 1% at $159.50 in extended trade. The company estimated first-quarter adjusted earnings to be between $2.31 and $2.41 per share from an…

Read More